<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569241</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2018/0130</org_study_id>
    <nct_id>NCT03569241</nct_id>
  </id_info>
  <brief_title>PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases</brief_title>
  <acronym>STORM</acronym>
  <official_title>PEACE V: A Randomized Phase II Trial for the Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A proportion of prostate cancer (PCa) patients develop relapse following curative local&#xD;
      treatment. Regional nodal recurrence is an emerging clinical situation since the introduction&#xD;
      of new molecular imaging methods in the restaging of recurrent prostate cancer. More&#xD;
      specifically, a subgroup of these patients is being diagnosed with a recurrence confined to&#xD;
      the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA&#xD;
      PET-CT. As there are no specific treatment recommendations for these type of patients,&#xD;
      different treatment approaches are currently used, mostly focusing on local ablative&#xD;
      treatments using radiotherapy or surgery. These treatments are coined metastasisdirected&#xD;
      therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent&#xD;
      risk of progression, and even cure limited regional nodal recurrences. Consequently, lifelong&#xD;
      palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed.&#xD;
&#xD;
      The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following&#xD;
      primary PCa treatment to either metastasis-directed therapy (MDT) (salvage lymph node&#xD;
      dissection, sLND or stereotactic body radiotherapy, SBRT) or MDT plus whole pelvis&#xD;
      radiotherapy (WPRT: 45 Gy in 25 fractions).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A proportion of prostate cancer (PCa) patients develop a local, regional (N1) or distant (M1)&#xD;
      relapse following curative local treatment. For both local and distant relapses, different&#xD;
      treatment recommendations are made in the guidelines (EAU guidelines 2016). However, the&#xD;
      entity regional nodal recurrence is not mentioned in the guidelines but is an emerging&#xD;
      clinical situation since the introduction of choline and more recently PSMA PET-CT in the&#xD;
      restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is&#xD;
      being diagnosed with a recurrence confined to the regional lymph nodes and limited in number&#xD;
      (oligorecurrence) using choline or PSMA PET-CT. As there are no specific treatment&#xD;
      recommendations for these type of patients, different treatment approaches are currently&#xD;
      used, mostly focusing on local ablative treatments using radiotherapy or surgery. These&#xD;
      treatments are coined metastasisdirected therapy (MDT). MDT in combination with or without&#xD;
      temporary ADT could delay the subsequent risk of metastases, and even cure limited regional&#xD;
      nodal recurrences. Consequently, lifelong palliative ADT, with its toxicity and excess in&#xD;
      non-cancer mortality might be postponed.&#xD;
&#xD;
      The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following&#xD;
      primary PCa treatment to either metastasis-directed therapy (MDT) (sLND or SBRT) or MDT plus&#xD;
      WPRT. In the recurrent PCa setting, 2 recent trials have suggested a progression-free and&#xD;
      even survival benefit of adding temporary ADT to local salvage prostate bed radiotherapy.&#xD;
      Consequently, this positive effect might also be applicable for regional recurrences.&#xD;
      Although the optimal duration of ADT is unknown, a minimal duration of 6 months of ADT seems&#xD;
      advisable in this setting and will be mandatory for both arms.&#xD;
&#xD;
      This trial will improve our insights in the pattern of recurrence following these treatment&#xD;
      modalities with the expectation that WPRT will reduce the number of nodal relapses, improving&#xD;
      metastasis-free survival and postponing the need for palliative systemic treatments while&#xD;
      maintaining quality-of-life. The current phase II trial will try to establish a golden&#xD;
      standard in the treatment of oligorecurrent nodal PCa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastases-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Metastasis-free survival will be defined as the time between randomization and the appearance of a metastatic recurrence (any M1) as suggested by choline, FACBC or PSMA PET-CT or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Progression free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Clinical Progression-free survival is defined as time between randomization and the appearance of a new recurrence (any N1 or M1) as suggested by PET-CT, symptoms related to progressive PCa, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>For patients who had previous RP at initial diagnosis, a biochemical recurrence is defined by any confirmed PSA rise above 0.20 ng/ml with a confirmatory rise at least 2 weeks later. For patients who had previous RT to the prostate at initial diagnosis, a biochemical recurrence is defined as the nadir + 2ng/ml (Phoenix definition). Non-responders are considered to have a biochemical recurrence in case a second measurement at least 2 weeks later confirms a rising PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity: acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Radiotherapy toxicity will be assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity: late toxicity</measure>
    <time_frame>2 year</time_frame>
    <description>Radiotherapy toxicity will be assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported QOL as per EORTC-QLQ C30</measure>
    <time_frame>2 year</time_frame>
    <description>Validated questionnaire assessing different health-related parameters (psychological, physical and social well-being) in cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported QOL as per EORTC-QLQ PR25</measure>
    <time_frame>2 year</time_frame>
    <description>Validated questionnaire assessing the health-related QOL of prostate cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific survival</measure>
    <time_frame>5 year</time_frame>
    <description>Cancer specific survival will be read as the time from trial randomization to the date of death due to prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>Overall survival will be read as the time from trial randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to start of hormonal treatment</measure>
    <time_frame>2 year</time_frame>
    <description>Time to hormonal treatment is defined as the time from trial randomization to start of hormonal treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration-resistant disease</measure>
    <time_frame>5 year</time_frame>
    <description>Time to castration resistant disease is defined as the time from trial randomization until castration resistant status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>economical evaluation</measure>
    <time_frame>2 year</time_frame>
    <description>Assessment of quality-adjusted-life-years with the EuroQol classification system (EQ-5D-5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity/specificity of PET-CT for the detection of nodal recurrences: limited to patients undergoing surgery</measure>
    <time_frame>3 months</time_frame>
    <description>Sensitivity/specificity of PET-CT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Oligometastatic Cancer</condition>
  <arm_group>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole pelvic radiotherapy</intervention_name>
    <description>addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment</description>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>metastasis-directed treatment</intervention_name>
    <description>stereotactic body radiotherapy</description>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>salvage Lymph Node Dissection</intervention_name>
    <description>metastasis-directed treatment</description>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>androgen deprivation therapy</intervention_name>
    <description>LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months</description>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven initial diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
          -  Biochemical relapse of prostate cancer following radical local prostate treatment&#xD;
             (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed&#xD;
             adjuvant/ salvage radiotherapy) according to the EAU guidelines 2016.&#xD;
&#xD;
          -  Following radical prostatectomy, patients with a biochemical relapse are eligible in&#xD;
             case a nodal relapse is detected in the pelvis even in the absence of prior&#xD;
             postoperative prostate bed radiotherapy (adjuvant or salvage).&#xD;
&#xD;
          -  In case of a suspected local recurrence following primary radiotherapy, a biopsy&#xD;
             should confirm local recurrence and patients with a confirmed local recurrence are&#xD;
             eligible in case they also undergo a local salvage therapy. If imaging rules out local&#xD;
             relapse, patients are eligible.&#xD;
&#xD;
          -  Nodal relapse in the pelvis on choline, PSMA or FACBC PET-CT with a maximum of 3&#xD;
             positive nodal lymph nodes. The upper limit of the pelvis is defined as the aortic&#xD;
             bifurcation.&#xD;
&#xD;
          -  WHO performance state 0-1&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent must be given&#xD;
             according to ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bone or visceral metastases&#xD;
&#xD;
          -  Para-aortic lymph node metastases (above the aortic bifurcation)&#xD;
&#xD;
          -  Local relapse in the prostate gland or prostate bed not suitable for a curative&#xD;
             treatment&#xD;
&#xD;
          -  Previous irradiation of the pelvic and or para-aortic nodes&#xD;
&#xD;
          -  Serum testosterone level &lt;50ng/dl or 1.7 nmol/L at time of randomization&#xD;
&#xD;
          -  Symptomatic metastases&#xD;
&#xD;
          -  Lymph node metastases in previously irradiated areas resulting in dose constraint&#xD;
             violation&#xD;
&#xD;
          -  Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)&#xD;
&#xD;
          -  Contraindications to androgen deprivation therapy&#xD;
&#xD;
          -  PSA rise while on active treatment with (LHRH-agonist, LHRH-antagonist, anti-androgen,&#xD;
             estrogen&#xD;
&#xD;
          -  Previous treatment with cytotoxic agent for PCa&#xD;
&#xD;
          -  Treatment during the past month with products known to influence PSA levels (e.g.&#xD;
             fluconazole, finasteride, corticosteroids,…)&#xD;
&#xD;
          -  Other active malignancy, except non-melanoma skin cancer or other malignancies with a&#xD;
             documented disease-free survival for a minimum of 3 years before randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piet Ost, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piet Ost, PhD</last_name>
    <phone>003293323015</phone>
    <email>piet.ost@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shankar Siva, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nathan Lawrentschuk, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piet Dirix, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ St-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Meersschout, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ St-Lucas</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lien Van De Voorde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Xavier Otte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Ameye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piet Ost, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Piet Ost, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Liefhooghe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Everaerts, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mouscron</name>
      <address>
        <city>Mouscron</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Junius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Scorsetti, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ciro Franzese, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vita-Salute San Raffaele University</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Briganti, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossella Di Franco, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Filippi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore-Don Calabria</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Alongi, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Niccolo Giaj Levra, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reino Heikkilä, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cruces University Hospital</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Gomez-Iturriaga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria IMQ</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Eíto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Lopez Campos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almudena Zapatero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitario Quironsalud</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Couñago, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospitalario de Navarra</name>
      <address>
        <city>Navarro</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Villafranca Iturre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Higuero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio José Conde-Moreno, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandros Papachristofilou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Radio-Onkologie</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Shelan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zilli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Martin Putora, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Guckenberger, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>metastasis-directed therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

